Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Revenue (2018 - 2025)

Historic Revenue for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to $17.2 million.

  • Arcturus Therapeutics Holdings' Revenue fell 5884.39% to $17.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $97.6 million, marking a year-over-year decrease of 3915.17%. This contributed to the annual value of $152.3 million for FY2024, which is 868.65% down from last year.
  • As of Q3 2025, Arcturus Therapeutics Holdings' Revenue stood at $17.2 million, which was down 5884.39% from $28.3 million recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' Revenue registered a high of $160.3 million during Q4 2022, and its lowest value of $2.0 million during Q2 2021.
  • Its 5-year average for Revenue is $32.2 million, with a median of $27.1 million in 2022.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' Revenue soared by 266653.43% in 2022, and later crashed by 8075.09% in 2023.
  • Arcturus Therapeutics Holdings' Revenue (Quarter) stood at $5.8 million in 2021, then soared by 2666.53% to $160.3 million in 2022, then crashed by 80.75% to $30.9 million in 2023, then fell by 26.22% to $22.8 million in 2024, then decreased by 24.66% to $17.2 million in 2025.
  • Its Revenue was $17.2 million in Q3 2025, compared to $28.3 million in Q2 2025 and $29.4 million in Q1 2025.